Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Loxo Oncology, Inc. (NASDAQ: LOXO).

Full DD Report for LOXO

You must become a subscriber to view this report.


Recent News from (NASDAQ: LOXO)

Your Cancer Highlight: Loxo Breaks Through Again, Now With Its Own Drug
The meteoric rise of Loxo Oncology (LOXO) has been fascinating to watch over the past 3 years, having gained over 1000 percent since 2015 on the back of unprecedented results, the potential of the world's first "tissue-agnostic" approval for a targeted therapy, and a massive partnership with B...
Source: SeekingAlpha
Date: September, 07 2018 08:00
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292
STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough T...
Source: GlobeNewswire
Date: September, 05 2018 06:45
Et Tu, Bruton?
Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales ...
Source: SeekingAlpha
Date: August, 30 2018 11:15
Loxo Oncology submits European MAA for larotrectinib
Loxo Oncology (NASDAQ: LOXO ) announces that its collaboration partner, Bayer, has submitted a marketing authorization application (MAA) for larotrectinib to the European Medicines Agency (EMA). More news on: Loxo Oncology, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 27 2018 05:54
Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib
STAMFORD, Conn., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that its collaboration partner, Bayer, has submitted a marketing authorizati...
Source: GlobeNewswire
Date: August, 27 2018 02:30
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2)
In my previous article on Loxo Oncology ( LOXO ), I introduced the challenges facing LOXO as they transition to becoming a commercial-stage biotech company. In that article, I discuss their R&D strategy, scientific platform, and upcoming clinical and regulatory milestones. In this art...
Source: SeekingAlpha
Date: August, 17 2018 15:54
Loxo Oncology: Out Of The Frying Pan And Into The Fire, Part 1
Loxo Oncology ( LOXO ) is a clinical-stage biopharmaceutical company developing precision, small molecule inhibitors to treat cancer. On May 29, 2018, the FDA accepted the New Drug Application ((NDA)) for Larotrectinib for the treatment of adult and pediatric patients with locally advanced or ...
Source: SeekingAlpha
Date: August, 14 2018 10:54
Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer
STAMFORD, Conn., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that abstracts from its LOXO-292 and larotrectinib programs have been accept...
Source: GlobeNewswire
Date: August, 10 2018 16:30
Loxo Oncology, Inc. (LOXO) CEO Dr. Josh Bilenker on Q2 2018 Results - Earnings Call Transcript
Loxo Oncology, Inc. (LOXO) Q2 2018 Results Earnings Conference Call August 09, 2018 08:00 AM ET Executives Pete Rahmer - IR, Endurance Advisors, LLC Dr. Josh Bilenker - CEO Jake Van Naarden - Chief Business Officer Jen Burstein - SPV, Finance Analysts Marc Frahm - Cowen ...
Source: SeekingAlpha
Date: August, 09 2018 14:45
Loxo Oncology beats by $0.15, beats on revenue
Loxo Oncology (NASDAQ: LOXO ): Q2 EPS of -$0.39 beats by $0.15 . More news on: Loxo Oncology, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 09 2018 06:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-08161.11160.97164.03159.43135,960
2018-05-17160.50167.53171.989158.012,757,852
2018-02-26114.91112.64116.00112.27248,500
2018-02-23111.99113.91114.71109.24204,249
2018-02-22110.38111.16113.50109.54371,296

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1237,74264,66958.3618Short
2018-12-1140,22766,09860.8596Short
2018-12-1026,98046,89757.5303Short
2018-12-0787,614159,38454.9704Short
2018-12-0623,67290,72126.0932Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LOXO.


About Loxo Oncology, Inc. (NASDAQ: LOXO)

Logo for Loxo Oncology, Inc. (NASDAQ: LOXO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $4,188,265,425 - 05/11/2018
  • Issue and Outstanding: 30,034,173 - 02/23/2018

 


Recent Filings from (NASDAQ: LOXO)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: LOXO)

Daily Technical Chart for (NASDAQ: LOXO)


Stay tuned for daily updates and more on (NASDAQ: LOXO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: LOXO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LOXO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LOXO and does not buy, sell, or trade any shares of LOXO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/